Trials / Completed
CompletedNCT00090038
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab | Dose, schedule,and duration specified in protocol |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2007-06-01
- Completion
- 2007-11-01
- First posted
- 2004-08-24
- Last updated
- 2009-10-20
Locations
45 sites across 11 countries: United States, Austria, Czechia, France, Germany, Lithuania, Romania, Russia, Sweden, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00090038. Inclusion in this directory is not an endorsement.